@article{MTMT:34747533, title = {Patients' persistent symptoms, clinician demographics and geo-economic factors are associated with choice of therapy for hypothyroidism by European thyroid specialists :$bThe "THESIS"* collaboration (*Treatment of Hypothyroidism in Europe by Specialists, an International Survey)}, url = {https://m2.mtmt.hu/api/publication/34747533}, author = {Roberto, Attanasio and Miloš, Žarković and Enrico, Papini and Nagy, Endre and Roberto, Negro and Petros, Perros and Ersin, Akarsu and Maria, Alevizaki and Göksun, Ayvaz and Tomasz, Bednarczuk and Biljana, Beleslin and Berta, Eszter and Bodor, Miklós and Anna, Maria Borissova and Mihail, Boyanov and Camille, Buffet and Maria-Cristina, Burlacu and Jasmina, Ciric and Juan, J. Díez and Harald, Dobnig and Valentin, V. Fadeyev and Benjamin, C. T. Field and Eric, Fliers and Dagmar, Führer and Juan, Carlos Galofré and Tommi, Hakala and Jan, Jiskra and Peter, A. Kopp and Michael, Krebs and Michal, Kršek and Martin, Kuzma and Mikael, Lantz and Ivica, Lazúrová and Laurence, Leenhardt and Vitaliy, Luchytskiy and Francisca, Marques Puga and Anne, McGowan and Saara, Metso and Carla, Moran and Tatyana, Morgunova and Dan, Alexandru Niculescu and Božidar, Perić and Tereza, Planck and Catalina, Poiana and Eyal, Robenshtok and Patrick, Olivier Rosselet and Marek, Ruchala and Kamilla, Ryom Riis and Alla, Shepelkevich and Mykola, D. Tronko and David, Unuane and Irfan, Vardarli and W., Edward Visser and Andromachi, Vryonidou and Younes, Ramazan Younes and Laszlo, Hegedus}, journal-iso = {THYROID}, journal = {THYROID}, unique-id = {34747533}, issn = {1050-7256}, year = {2024}, eissn = {1557-9077} } @article{MTMT:34564621, title = {Serum afamin and its implications in adult growth hormone deficiency: a prospective GH-withdrawal study}, url = {https://m2.mtmt.hu/api/publication/34564621}, author = {Ratku, Balázs and Lőrincz, Hajnalka and Bak-Csiha, Sára and Sebestyén, Veronika and Berta, Eszter and Bodor, Miklós and Nagy, Endre and Szabó, Zoltán and Harangi, Mariann and Somodi, Sándor}, doi = {10.3389/fendo.2024.1348046}, journal-iso = {FRONT ENDOCRINOL}, journal = {FRONTIERS IN ENDOCRINOLOGY}, volume = {15}, unique-id = {34564621}, issn = {1664-2392}, year = {2024}, eissn = {1664-2392}, orcid-numbers = {Somodi, Sándor/0000-0002-3615-2300} } @article{MTMT:34484390, title = {Characteristics of specialists treating hypothyroid patients: the “THESIS” collaborative}, url = {https://m2.mtmt.hu/api/publication/34484390}, author = {Žarković, Miloš and Attanasio, Roberto and Nagy, Endre and Negro, Roberto and Papini, Enrico and Perros, Petros and Cohen, Chagit Adler and Akarsu, Ersin and Alevizaki, Maria and Ayvaz, Göksun and Bednarczuk, Tomasz and Berta, Eszter and Bodor, Miklós and Borissova, Anna Maria and Boyanov, Mihail and Buffet, Camille and Burlacu, Maria-Cristina and Ćirić, Jasmina and Díez, Juan J. and Dobnig, Harald and Fadeyev, Valentin and Field, Benjamin C. T. and Fliers, Eric and Frølich, Jacob Stampe and Führer, Dagmar and Galofré, Juan Carlos and Hakala, Tommi and Jiskra, Jan and Kopp, Peter and Krebs, Michael and Kršek, Michal and Kužma, Martin and Lantz, Mikael and Lazúrová, Ivica and Leenhardt, Laurence and Luchytskiy, Vitaliy and McGowan, Anne and Melo, Miguel and Metso, Saara and Moran, Carla and Morgunova, Tatyana and Mykola, Tronko and Beleslin, Biljana Nedeljković and Niculescu, Dan Alexandru and Perić, Božidar and Planck, Tereza and Poiana, Catalina and Puga, Francisca Marques and Robenshtok, Eyal and Rosselet, Patrick and Ruchala, Marek and Riis, Kamilla Ryom and Shepelkevich, Alla and Unuane, David and Vardarli, Irfan and Visser, W. Edward and Vrionidou, Andromachi and Younes, Younes R. and Yurenya, Elena and Hegedüs, Laszlo}, doi = {10.3389/fendo.2023.1225202}, journal-iso = {FRONT ENDOCRINOL}, journal = {FRONTIERS IN ENDOCRINOLOGY}, volume = {14}, unique-id = {34484390}, issn = {1664-2392}, year = {2023}, eissn = {1664-2392}, pages = {1-11} } @article{MTMT:34391921, title = {Kezelés nélkül javuló acromegalia a pandémia alatt}, url = {https://m2.mtmt.hu/api/publication/34391921}, author = {Dániel, Eszter and Nagy, B. Edit and Nagy, Endre and Erdei, Annamária}, journal-iso = {METABOLIZMUS}, journal = {METABOLIZMUS}, volume = {21}, unique-id = {34391921}, issn = {1589-7311}, year = {2023}, pages = {86-89} } @article{MTMT:34347406, title = {Use of thyroid hormones in hypothyroid and euthyroid patients: a 2022 THESIS questionnaire survey of members of the Latin American Thyroid Society (LATS)}, url = {https://m2.mtmt.hu/api/publication/34347406}, author = {Cassemiro, Jessica F. and Ilera, Veronica and Batalles, Stella and Reyes, Adriana and Nagy, Endre and Papini, Enrico and Perros, Petros and Hegedus, Laszlo and Ramos, Helton Estrela}, doi = {10.1186/s13044-023-00182-4}, journal-iso = {THYROID RES}, journal = {THYROID RESEARCH}, volume = {16}, unique-id = {34347406}, issn = {1756-6614}, abstract = {PurposeInconsistencies in the medical management of hypothyroidism have been reported between endocrinologists in different countries. This study aimed to identify the attitudes of Latin America thyroid specialists towards the use of thyroid hormones.MethodsOnline survey of members of the Latin America Thyroid Society.Results81/446 (18.2%) completed the questionnaire. Levothyroxine (LT4) was the initial treatment of choice for all respondents. 56.8% would consider LT4 use in biochemically euthyroid patients: infertile women with elevated anti-thyroid antibodies (46.9%), resistant depression (17.3%) and growing goiter (12%). Most respondents preferred tablets (39.5%) over liquid formulations (21.0%) or soft gel capsules (22.2%) and would not consider switching formulations in patients with persistent symptoms. 39.5% would never use LT4 + liothyronine (LT3) combination therapy in symptomatic euthyroid patients, due to low quality evidence for benefit. 60.5% reported that persistence of symptoms despite normal TSH is rare (below 5% of patients) and its prevalence has been stable over the last five years. Psychosocial factors (84.0%), comorbidities (86.4%) and the patient unrealistic expectation (72.8%) were considered the top three explanations for this phenomenon.ConclusionLT4 tablets is the treatment of choice for hypothyroidism. A significant proportion of respondents would use LT4 in some groups of euthyroid individuals, contrasting the recommendations of the major clinical practice guideline indications. LT4 + LT3 combination treatment in euthyroid symptomatic patients was considered by nearly 50%. Practices based on weak or absent evidence included use of thyroid hormones for euthyroid subjects by 56.8% of respondents and use of LT4 + LT3 treatment by 60.5% of respondents for patients with persistent symptoms. In contrast to many European countries, LATS respondents report a low and unchanged proportion of dissatisfied patients over the last five years.}, keywords = {Survey; liothyronine; HYPOTHYROIDISM; levothyroxine; euthyroidism; Latin American Thyroid Society}, year = {2023} } @article{MTMT:34280731, title = {A felnőttkori növekedésihormon-hiány szív- és érrendszeri szövődményei}, url = {https://m2.mtmt.hu/api/publication/34280731}, author = {Ratku, Balázs and Sebestyén, Veronika and Szelesné Árokszállási, Andrea and Erdei, Annamária and Berta, Eszter and Szabó, Zoltán and Bodor, Miklós and Nagy, Endre and Somodi, Sándor}, doi = {10.1556/650.2023.32890}, journal-iso = {ORV HETIL}, journal = {ORVOSI HETILAP}, volume = {164}, unique-id = {34280731}, issn = {0030-6002}, abstract = {A növekedési hormon–inzulinszerű növekedési faktor-1 (GH–IGF-1-) tengely jelentős szerepet tölt be a cardiovascularis rendszer fiziológiás működésének fenntartásában. Az elmúlt évtizedek kutatási eredményei alapján a GH–IGF-1-tengely részt vesz a perifériás ellenállás szabályozásában, és hozzájárul a normális szívizomtömeg és balkamra-funkció megtartásához. A GH–IGF-1-tengely érfalprotektív funkciói az atherosclerosis ellenében hatnak. Ellentétben a gyermekkori GH-hiánnyal, amelynél a betegség egyértelmű biológiai következménye a gyermek növekedésbeli visszamaradása, a felnőttkori növekedésihormon-hiánynak (adult growth hormone deficiency – AGHD) nincsenek specifikus tünetei. Az AGHD klinikai megjelenését a cardiovascularis rizikótényezők halmozódása jellemzi, amely miatt a klinikai kép leginkább a metabolicus szindrómához hasonlítható. Újabb kutatások AGHD esetében a tradicionális rizikótényezők mellett krónikus kisfokú gyulladás, prothromboticus állapot és oxidatív stressz jelenlétére is rámutattak, amelyek szintén közrejátszhatnak a fokozott kardiometabolikus rizikó kialakulásában. A tartós GH-szubsztitúció AGHD-betegek esetében a lipidprofil jelentős javulását eredményezi, és kedvező hatással van a testösszetételre, a szívizomtömegre, az endothelfunkcióra, valamint az újonnan felismert, nem tradicionális rizikótényezőkre is. A betegséggel összefüggő fokozott mortalitás a mai felfogás szerint multikauzális, és nem vezethető vissza csupán a GH hiányára. A kedvezőtlen mortalitásért az etiológia, az alkalmazott kezelés és az egyéb hypophysishormon-hiányok kezelésének nehézsége is felelős lehet. Mindazonáltal hypopituitarismus esetében optimális, a GH-pótlást is magában foglaló hormonszubsztitúcióval az átlagpopulációéhoz közelítő mortalitás érhető el. Orv Hetil. 2023; 164(41): 1616–1627.}, year = {2023}, eissn = {1788-6120}, pages = {1616-1627}, orcid-numbers = {Somodi, Sándor/0000-0002-3615-2300} } @article{MTMT:34039103, title = {Diagnosis and Management of Takotsubo Syndrome in Acute Aneurysmal Subarachnoid Hemorrhage: A Comprehensive Review}, url = {https://m2.mtmt.hu/api/publication/34039103}, author = {Szántó, Dorottya and Luterán, Péter and Gál, Judit and Nagy, Endre and Fülesdi, Béla and Molnár, Csilla}, doi = {10.31083/j.rcm2406177}, journal-iso = {REV CARDIOVASC MED}, journal = {REVIEWS IN CARDIOVASCULAR MEDICINE}, volume = {24}, unique-id = {34039103}, issn = {1530-6550}, abstract = {Takotsubo syndrome (TS) is a frequent complication of subarachnoid hemorrhage (SAH), especially in massive SAH with severe neuro-logical damage. The initial presentation of TS is similar to acute coronary syndrome, causing differential diagnostic issues. Unnecessary diagnostic steps and uncertainty in therapy may delay the definitive treatment of the aneurysm, therefore increasing the risk of rebleeding. The purpose of this review is to summarize the latest knowledge on the diagnosis and therapy of TS in SAH and to provide a diagnostic and therapeutic algorithm for the acute phase, promoting the early definitive treatment of the aneurysm. Rapid hemodynamic stabilization and early aneurysm securing are key points in reducing the risk of delayed cerebral ischemia and improving outcomes. In acute SAH noninvasive bedside diagnostic methods are preferred and securing the aneurysm is the priority. The combination of electrocardiography, cardiac biomarkers, and echocardiography is of great importance in differentiating TS from acute myocardial infarction. The risk-benefit ratio of coronary angiography should be carefully and individually considered and its use should be limited to patients with strong evi-dence of myocardial ischemia, after the successful endovascular treatment of the aneurysm. Invasive hemodynamic monitoring may be beneficial in cases of cardiogenic shock or pulmonary edema. In patients with hemodynamical instability secondary to TS, the use of non-catecholamine inotropes, especially levosimendan is recommended. In refractory hypotension, mechanical support should be con-sidered. The left ventricular function improves within days to months after the acute event, low initial ejection fraction may predispose to delayed recovery.}, year = {2023}, eissn = {2153-8174} } @article{MTMT:33870288, title = {Hypothyroidism and Somatization: Results from E-Mode Patient Self-Assessment of Thyroid Therapy, a Cross-Sectional, International Online Patient Survey}, url = {https://m2.mtmt.hu/api/publication/33870288}, author = {Perros, Petros and Nagy, Endre and Papini, Enrico and van der Feltz-Cornelis, Christina Maria and Weetman, Anthony Peter and Hay, Harriet Alexandra and Abad-Madronero, Juan and Tallett, Amy Johanna and Bilas, Megan and Lakwijk, Peter and Poots, Alan J. and Hegedus, Laszlo}, doi = {10.1089/thy.2022.0641}, journal-iso = {THYROID}, journal = {THYROID}, volume = {33}, unique-id = {33870288}, issn = {1050-7256}, abstract = {Background: Between 10% and 15% of hypothyroid patients experience persistent symptoms despite achieving biochemical euthyroidism. Unexplained persistent symptoms can be a sign of somatization. This is associated with distress and high health care resource use and can be classified as somatic symptom disorder (SSD). Prevalence rates for SSD differ depending on classification criteria and how they are ascertained, varying between 4% and 25%. As this has not been studied in hypothyroid patients before, the aim of this study was to document somatization in people with hypothyroidism and to explore associations with other patient characteristics and outcomes.Methods: Online, multinational cross-sectional survey of individuals with self-reported, treated hypothyroidism, which included the validated Patient Health Questionnaire-15 (PHQ-15) for assessment of somatization. Chi-squared tests with the Bonferroni correction were used to explore outcomes for respondents with a PHQ-15 score >= 10 (probable somatic symptom disorder [pSSD]) versus a PHQ-15 score <10 (absence of SSD).Results: A total of 3915 responses were received, 3516 of which contained the valid PHQ-15 data (89.8%). The median score was 11.3 (range 0-30 [confidence interval 10.9-11.3]). The prevalence of pSSD was 58.6%. Associations were found between pSSD and young age (p < 0.001), women (p < 0.001), not working (p < 0.001), having below average household income (p < 0.001), being treated with levothyroxine (LT4) (rather than combination of LT4 and L-triiodothyronine [LT3], LT3 alone, or desiccated thyroid extract) (p < 0.001), expression of the view that the thyroid medication taken did not control the symptoms of hypothyroidism well (p < 0.001), and with number of comorbidities (p < 0.001). pSSD was associated with respondent attribution of most PHQ-15 symptoms to the hypothyroidism or its treatment (p < 0.001), dissatisfaction with care and treatment of hypothyroidism (p < 0.001), a negative impact of hypothyroidism on daily living (p < 0.001), and with anxiety and low mood/depression (p < 0.001).Conclusions: This study demonstrates a high prevalence of pSSD among people with hypothyroidism and associations between pSSD and negative patient outcomes, including a tendency to attribute persistent symptoms to hypothyroidism or its treatment. SSD may be an important determinant of dissatisfaction with treatment and care among some hypothyroid patients.}, keywords = {questionnaire; Survey; HYPOTHYROIDISM; levothyroxine; somatization; L-triiodothyronine}, year = {2023}, eissn = {1557-9077}, pages = {927-939} } @article{MTMT:33699902, title = {Case report: Metastatic pancreatic neuroendocrine tumour associated with portal vein thrombosis; successful management with subsequent pregnancies}, url = {https://m2.mtmt.hu/api/publication/33699902}, author = {Sira, Lívia and Zsíros, Noémi and Bidiga, László and Barna, Sándor Kristóf and Kanyári, Zsolt and Nagy, Edit B. and Guillaume, Nicolas and Wild, Damian and Rázsó, Katalin and Andó, Szilvia and Balogh, István and Nagy, Endre and Balogh, Zoltán}, doi = {10.3389/fendo.2023.1095815}, journal-iso = {FRONT ENDOCRINOL}, journal = {FRONTIERS IN ENDOCRINOLOGY}, volume = {14}, unique-id = {33699902}, issn = {1664-2392}, abstract = {Background: Splanchnic vein thrombosis due to co-existing metastatic pancreatic neuroendocrine tumour (pNET) and JAK2V617F mutation is a rare condition. Case report: Here we present a case of a young woman with complete remission of a non-functioning grade 2 pNET with unresectable liver metastases, coexisting with JAK2V617F mutation. Splenectomy and distal pancreatectomy were performed. Neither surgical removal, nor radiofrequency ablation of the liver metastases was possible. Therefore, somatostatin analogue (SSA) and enoxaparine were started. Peptide receptor radionuclide therapy (PRRT) was given in 3 cycles 6-8 weeks apart. Genetic testing revealed no multiple endocrine neoplasia type 1 (MEN-1) gene mutations. After shared decision making with the patient, she gave birth to two healthy children, currently 2 and 4 years old. On pregnancy confirmation, SSA treatment was interrupted and resumed after each delivery. Ten years after the diagnosis of pNET, no tumour is detectable by MRI or somatostatin receptor scintigraphy. PRRT followed by continuous SSA therapy, interrupted only during pregnancies, resulted in complete remission and enabled the patient to complete two successful pregnancies.}, year = {2023}, eissn = {1664-2392} } @article{MTMT:33602815, title = {Considerable interobserver variation calls for unambiguous definitions of thyroid nodule ultrasound characteristics.}, url = {https://m2.mtmt.hu/api/publication/33602815}, author = {Solymosi, Tamás and Hegedűs, Laszlo and Bonnema, Steen J and Frasoldati, Andrea and Jambor, Laszlo and Karányi, Zsolt and Kovacs, Gabor L and Papini, Enrico and Rucz, Károly and Russ, Gilles and Nagy, Endre}, doi = {10.1530/ETJ-22-0134}, journal-iso = {EUR THYROID J}, journal = {EUROPEAN THYROID JOURNAL}, volume = {12}, unique-id = {33602815}, issn = {2235-0640}, abstract = {Thyroid nodule ultrasound characteristics are used as indication for FNA, usually as the basis for Thyroid Imaging Reporting and Data System (TIRADS) score calculation. Few studies on inter-observer variation are available, all of which are based on analysis of preselected still ultrasound images and often lack surgical confirmation.After the blinded online evaluation of video-recordings of the ultrasound examinations of 47 consecutive malignant and 76 consecutive benign thyroid lesions, 7 experts from 7 thyroid centers answered 17 TIRADS-related questions. Surgical histology was the reference standard. Inter-observer variations of each ultrasound characteristic were compared using Gwet's AC1 inter-rater coefficients; higher values mean better concordance, the maximum being 1.0.On a scale from 0.0 to 1.0, the Gwet's AC1 values were 0.34, 0.53, 0.72, 0.79 for the four most important features in decision making, i.e. irregular margins, microcalcifications, echogenicity and extrathyroidal extension, respectively. The concordance in the discrimination between mildly/moderately and very hypoechogenic nodules was 0.17. The smaller the nodule size the better the agreement in echogenicity, and the larger the nodule size the better the agreement on the presence of microcalcifications. Extrathyroidal extension, was correctly identified in just 45.8% of the cases.Examination of video recordings, closely simulating the real-world situation, revealed substantial inter-observer variation in the interpretation of each of the four most important ultrasound characteristics. In view of the importance for management of thyroid nodules, unambiguous and widely accepted definitions of each nodule characteristic are warranted, although it remains to be investigated whether this diminishes observer-variation.}, year = {2023}, eissn = {2235-0802} }